Literature DB >> 20570689

Flavin-containing monooxygenase-3: induction by 3-methylcholanthrene and complex regulation by xenobiotic chemicals in hepatoma cells and mouse liver.

Trine Celius1, Andrea Pansoy, Jason Matthews, Allan B Okey, Marilyn C Henderson, Sharon K Krueger, David E Williams.   

Abstract

Flavin-containing monooxygenases often are thought not to be inducible but we recently demonstrated aryl hydrocarbon receptor (AHR)-dependent induction of FMO mRNAs in mouse liver by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (Celius et al., Drug Metab Dispos 36:2499, 2008). We now evaluated FMO induction by other AHR ligands and xenobiotic chemicals in vivo and in mouse Hepa1c1c7 hepatoma cells (Hepa-1). In mouse liver, 3-methylcholanthrene (3MC) induced FMO3 mRNA 8-fold. In Hepa-1 cells, 3MC and benzo[a]pyrene (BaP) induced FMO3 mRNA >30-fold. Induction by 3MC and BaP was AHR dependent but, surprisingly, the potent AHR agonist, TCDD, did not induce FMO3 mRNA in Hepa-1 cells nor did chromatin immunoprecipitation assays detect recruitment of AHR or ARNT to Fmo3 regulatory elements after exposure to 3MC in liver or in Hepa-1 cells. However, in Hepa-1, 3MC and BaP (but not TCDD) caused recruitment of p53 protein to a p53 response element in the 5'-flanking region of the Fmo3 gene. We tested the possibility that FMO3 induction in Hepa-1 cells might be mediated by Nrf2/anti-oxidant response pathways, but agents known to activate Nrf2 or to induce oxidative stress did not affect FMO3 mRNA levels. The protein synthesis inhibitor, cycloheximide (which causes "superinduction" of CYP1A1 mRNA in TCDD-treated cells), by itself caused dramatic upregulation (>300-fold) of FMO3 mRNA in Hepa-1 suggesting that cycloheximide prevents synthesis of a labile protein that suppresses FMO3 expression. Although FMO3 mRNA is highly induced by 3MC or TCDD in mouse liver and in Hepa-1 cells, FMO protein levels and FMO catalytic function showed only modest elevation. (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20570689      PMCID: PMC2906660          DOI: 10.1016/j.taap.2010.05.018

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  61 in total

Review 1.  Regulatory polymorphisms and their contribution to interindividual differences in the expression of enzymes influencing drug and toxicant disposition.

Authors:  Ronald N Hines; Sevasti B Koukouritaki; Mark T Poch; Michael C Stephens
Journal:  Drug Metab Rev       Date:  2008       Impact factor: 4.518

2.  Characterization of a new cytochrome P450 enzyme, CYP2S1, in rats: its regulation by aryl hydrocarbon receptor agonists.

Authors:  Subrata Deb; Stelvio M Bandiera
Journal:  Toxicology       Date:  2009-10-31       Impact factor: 4.221

3.  Nitric oxide-dependent proteasomal degradation of cytochrome P450 2B proteins.

Authors:  Choon-Myung Lee; Bong-Yoon Kim; Lian Li; Edward T Morgan
Journal:  J Biol Chem       Date:  2007-11-09       Impact factor: 5.157

4.  Aryl hydrocarbon receptor-dependent induction of flavin-containing monooxygenase mRNAs in mouse liver.

Authors:  Trine Celius; Steven Roblin; Patricia A Harper; Jason Matthews; Paul C Boutros; Raimo Pohjanvirta; Allan B Okey
Journal:  Drug Metab Dispos       Date:  2008-09-02       Impact factor: 3.922

5.  Metabolism of the anti-tuberculosis drug ethionamide by mouse and human FMO1, FMO2 and FMO3 and mouse and human lung microsomes.

Authors:  Marilyn C Henderson; Lisbeth K Siddens; Jeffrey T Morré; Sharon K Krueger; David E Williams
Journal:  Toxicol Appl Pharmacol       Date:  2008-10-01       Impact factor: 4.219

6.  Human flavin-containing monooxygenase 2.1 catalyzes oxygenation of the antitubercular drugs thiacetazone and ethionamide.

Authors:  Asvi A Francois; Clinton R Nishida; Paul R Ortiz de Montellano; Ian R Phillips; Elizabeth A Shephard
Journal:  Drug Metab Dispos       Date:  2008-10-23       Impact factor: 3.922

7.  Sulforaphane induces CYP1A1 mRNA, protein, and catalytic activity levels via an AhR-dependent pathway in murine hepatoma Hepa 1c1c7 and human HepG2 cells.

Authors:  Anwar Anwar-Mohamed; Ayman O S El-Kadi
Journal:  Cancer Lett       Date:  2008-11-13       Impact factor: 8.679

8.  Patterns of dioxin-altered mRNA expression in livers of dioxin-sensitive versus dioxin-resistant rats.

Authors:  Monique A Franc; Ivy D Moffat; Paul C Boutros; Jouni T Tuomisto; Jouko Tuomisto; Raimo Pohjanvirta; Allan B Okey
Journal:  Arch Toxicol       Date:  2008-05-09       Impact factor: 5.153

Review 9.  Characterization and expression of extrahepatic CYP2S1.

Authors:  Subrata Deb; Stelvio M Bandiera
Journal:  Expert Opin Drug Metab Toxicol       Date:  2009-04       Impact factor: 4.481

10.  Isoform distinct time-, dose-, and castration-dependent alterations in flavin-containing monooxygenase expression in mouse liver after 2,3,7,8-tetrachlorodibenzo-p-dioxin treatment.

Authors:  Rachel M Novick; Chad M Vezina; Adnan A Elfarra
Journal:  Biochem Pharmacol       Date:  2009-12-28       Impact factor: 5.858

View more
  11 in total

1.  Analysis of changes in hepatic gene expression in a murine model of tolerance to acetaminophen hepatotoxicity (autoprotection).

Authors:  Meeghan A O'Connor; Petra Koza-Taylor; Sarah N Campion; Lauren M Aleksunes; Xinsheng Gu; Ahmed E Enayetallah; Michael P Lawton; José E Manautou
Journal:  Toxicol Appl Pharmacol       Date:  2013-10-11       Impact factor: 4.219

Review 2.  Flavin-containing monooxygenases in aging and disease: Emerging roles for ancient enzymes.

Authors:  Ryan Rossner; Matt Kaeberlein; Scott F Leiser
Journal:  J Biol Chem       Date:  2017-05-17       Impact factor: 5.157

3.  Relationship between serum trimethylamine N-oxide and exposure to dioxin-like pollutants.

Authors:  Michael C Petriello; Richard Charnigo; Manjula Sunkara; Sony Soman; Marian Pavuk; Linda Birnbaum; Andrew J Morris; Bernhard Hennig
Journal:  Environ Res       Date:  2018-01-30       Impact factor: 6.498

4.  Dioxin-like pollutants increase hepatic flavin containing monooxygenase (FMO3) expression to promote synthesis of the pro-atherogenic nutrient biomarker trimethylamine N-oxide from dietary precursors.

Authors:  Michael C Petriello; Jessie B Hoffman; Manjula Sunkara; Banrida Wahlang; Jordan T Perkins; Andrew J Morris; Bernhard Hennig
Journal:  J Nutr Biochem       Date:  2016-04-01       Impact factor: 6.048

Review 5.  Emerging roles of xenobiotic detoxification enzymes in metabolic diseases.

Authors:  Michael C Petriello; Jessie B Hoffman; Andrew J Morris; Bernhard Hennig
Journal:  Rev Environ Health       Date:  2017-03-01       Impact factor: 3.458

6.  Effects of salinity acclimation on the expression and activity of Phase I enzymes (CYP450 and FMOs) in coho salmon (Oncorhynchus kisutch).

Authors:  Ramon Lavado; Rosaura Aparicio-Fabre; Daniel Schlenk
Journal:  Fish Physiol Biochem       Date:  2013-08-08       Impact factor: 2.794

7.  Differential Fmo3 gene expression in various liver injury models involving hepatic oxidative stress in mice.

Authors:  Swetha Rudraiah; Jamie E Moscovitz; Ajay C Donepudi; Sarah N Campion; Angela L Slitt; Lauren M Aleksunes; José E Manautou
Journal:  Toxicology       Date:  2014-09-02       Impact factor: 4.221

8.  Tolerance to acetaminophen hepatotoxicity in the mouse model of autoprotection is associated with induction of flavin-containing monooxygenase-3 (FMO3) in hepatocytes.

Authors:  Swetha Rudraiah; Philip R Rohrer; Igor Gurevich; Michael J Goedken; Theodore Rasmussen; Ronald N Hines; José E Manautou
Journal:  Toxicol Sci       Date:  2014-06-27       Impact factor: 4.849

9.  Downregulation of mouse hepatic CYP3A protein by 3-methylcholanthrene does not require cytochrome P450-dependent metabolism.

Authors:  Chunja Lee; Xinxin Ding; David S Riddick
Journal:  Drug Metab Dispos       Date:  2013-07-11       Impact factor: 3.922

10.  Oxidative stress-responsive transcription factor NRF2 is not indispensable for the human hepatic Flavin-containing monooxygenase-3 (FMO3) gene expression in HepG2 cells.

Authors:  Swetha Rudraiah; Xinsheng Gu; Ronald N Hines; José E Manautou
Journal:  Toxicol In Vitro       Date:  2015-11-23       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.